Key clinical point: Patients with oligometastatic non–small cell lung cancer (NSCLC) have better outcomes when treated with local consolidative therapy than with maintenance therapy or observation.

Major finding: Patients treated with local consolidative therapy had a median overall survival of 41.2 months, compared with 17.0 months among patients treated with maintenance therapy or observation (P = .017).

Study details: A phase 2 randomized trial involving 49 patients with stage IV non–small cell lung cancer who had 3 or fewer metastases.

Disclosures: The study was funded by MD Anderson Cancer Center, The Mohaymen Sahebzadah Family Philanthropic Grant, and the National Cancer Institute, National Institutes of Health. The authors disclosed relationships with Merck, Bristol-Myers Squibb, AstraZeneca, and others.